ArticleNeuro-oncology2017
Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
Article in Neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Diagnostic Value of PET Tracers in Differentiating Glioma Tumor Recurrence from Treatment-Related Changes: A Systematic Review and Meta-Analysis.AJNR. American journal of neuroradiology · 2025Pooled it
- Machine learning imaging applications in the differentiation of true tumour progression from treatment-related effects in brain tumours: A systematic review and meta-analysis.Journal of medical imaging and radiation oncology · 2022Pooled it
- Isocitrate Dehydrogenase-Mutant Astrocytomas: Risk Stratification and Therapeutic Advance.MedComm · 2026Review
- Decreased T2-signal intensities indicate positive response to front-line radiotherapy in pediatric low-grade gliomas.La Radiologia medica · 2026Article
- Incidence and time course of new contrast-enhancing lesions on MRI after proton versus photon radiotherapy in glioma patients.Neuroradiology · 2026Article
- RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology.Japanese journal of radiology · 2025Review
- Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study.Radiation oncology (London, England) · 2025Article
- A volumetric analysis of timing and duration of T2/FLAIR changes on MRI following radiation therapy in patients with low-grade IDH-mutant glioma.Neuro-oncology practice · 2025Article
- Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3.Frontiers in oncology · 2025Article
- Systemic inflammatory markers and volume of enhancing tissue on post-contrast T1w MRI images in differentiating true tumor progression from pseudoprogression in high-grade glioma.Clinical and translational radiation oncology · 2024Article
- Digital "flipbooks" for enhanced visual assessment of simple and complex brain tumors.Neuro-oncology · 2024Article
- Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- TCAF2 drives glioma cellular migratory/invasion properties through STAT3 signaling.Molecular and cellular biochemistry · 2024Article
- Histopathologically confirmed radiation-induced damage of the brain - an in-depth analysis of radiation parameters and spatio-temporal occurrence.Radiation oncology (London, England) · 2023Article
- RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Post-chemo-radiotherapy response and pseudo-progression evaluation on glioma cell types by multi-parametric magnetic resonance imaging: a prospective study.BMC medical imaging · 2023Article
- Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy.Current treatment options in oncology · 2023Review
- Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- Diffusion-weighted imaging and arterial spin labeling radiomics features may improve differentiation between radiation-induced brain injury and glioma recurrence.European radiology · 2023Article
- Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.Neuro-oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the incidence of pseudo-progressive disease (psPD), or pseudoprogression, in low-grade glioma (LGG) is unknown, we retrospectively investigated this phenomenon in a cohort of LGG patients given radiotherapy (RT). Methods: All MRI scans and clinical data from patients with histologically proven LGG treated with radiation between 2000 and 2011 were reviewed. PsPD was scored when a new enhancing lesion occurred after RT and subsequently disappeared or remained stable for at least a year without therapy, including dexamethasone. Results: Sixty-three out of 71 patients who received RT for LGG were deemed eligible for evaluation of psPD. The median follow-up was 5 years (range 1‒10 y). PsPD was seen in 13 patients (20.6%). PsPD occurred after a median of 12 months with a range of 3-78 months. The median duration of psPD was 6 months, with a range of 2-26 months and always occurred within the RT high dose fields of at least 45 Gy. The area of the enhancement at the time of psPD was significantly smaller compared with the area of enhancement during "true" progression (median size 54mm2 [range 12-340mm2] vs 270mm2 [range 30-3420mm2], respectively; P = .009). Conclusions: PsPD occurs frequently in LGG patients receiving RT. This supports the policy to postpone a new line of treatment until progression is evident, especially when patients have small contrast enhancing lesions within the RT field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.